Bongiolatti Stefano, Mugnaini Giovanni, Salvicchi Alberto, Gonfiotti Alessandro, Borgianni Sara, Viggiano Domenico, Voltolini Luca
Thoracic Surgery Unit, Careggi University Hospital, Florence, Italy.
Thoracic Surgery Unit, University Hospital of Siena, Siena, Italy.
J Thorac Dis. 2025 Mar 31;17(3):1561-1569. doi: 10.21037/jtd-24-1431. Epub 2025 Mar 27.
Lung segmentectomy is widely used to treat early-stage non-small cell lung cancer (NSCLC), but the risk of local recurrence in the ipsilateral lobe is increased and the surgical treatment of the local recurrence could be a real challenge. The aim of this study is to report our experience in a consecutive series of patients undergoing completion lobectomy (CL) after thoracoscopic segmentectomy.
We retrospectively reviewed all the medical charts of the patients who underwent thoracoscopic segmentectomy for early-stage NSCLC (cIA) between January 2015 and December 2023, focusing on patients who had NSCLC recurrence in the ipsilateral lobe treated with CL.
Among the 263 segmentectomies performed, 13 patients (4.9%) experienced local recurrence in the ipsilateral remaining lobe, of whom 9 (3.4%) underwent CL, including 5 in the left upper lobe, with a median interval of 31 months between procedures. All patients underwent CL through thoracotomy with the need of central isolation in 5/9 (55.5%); rupture of the pulmonary artery occurred two patients and vascular sleeve resection was necessary in one. No postoperative deaths were observed, complications occurred in 5/9 patients with major complications, defined as Clavien-Dindo grade >3b, in 2/9 (22.2%) patients. Median hospital stay was 11 days. At the end of follow-up 2 patients had distant recurrence 12 median months after the CL.
CL in the left side could be considered a challenging procedure also after minimally invasive segmentectomy and we consider safe to perform CL with thoracotomy due to a scar tissue formation between the bronco-vascular structures leading the need for extensive hilar dissection and central isolation of the pulmonary artery.
肺段切除术广泛应用于早期非小细胞肺癌(NSCLC)的治疗,但同侧肺叶局部复发风险增加,对局部复发的手术治疗可能是一项真正的挑战。本研究的目的是报告我们对一系列连续接受胸腔镜肺段切除术后完成肺叶切除术(CL)患者的经验。
我们回顾性分析了2015年1月至2023年12月期间因早期NSCLC(cIA)接受胸腔镜肺段切除术患者的所有病历,重点关注同侧肺叶复发并接受CL治疗的患者。
在263例肺段切除术中,13例(4.9%)患者同侧剩余肺叶出现局部复发,其中9例(3.4%)接受了CL,包括左上叶5例,两次手术之间的中位间隔为31个月。所有患者均通过开胸手术进行CL,其中5/9(55.5%)需要进行中心隔离;2例患者发生肺动脉破裂,1例需要进行血管袖状切除术。未观察到术后死亡,5/9患者出现并发症,其中2/9(22.2%)患者发生严重并发症,定义为Clavien-Dindo分级>3b。中位住院时间为11天。随访结束时,2例患者在CL术后12个月中位时间出现远处复发。
左侧CL即使在微创肺段切除术后也可能是一项具有挑战性的手术,由于支气管血管结构之间形成瘢痕组织,导致需要广泛的肺门解剖和肺动脉中心隔离,我们认为开胸进行CL是安全的。